Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2019 2020 2021 2022 2023 2024 2025
Months
January February March April May June July August September October November December
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Number of NRF-rated researchers increases in 2012
2012-10-29

29 October 2012

Three researchers at the University of the Free State received B-ratings for 2013 from the National Research Foundation (NRF). Prof. Johan Henning, Dean of Law, obtained the highest rating in his field of mercantile law in South Africa, a B1.

Prof. Jackie Naudé from Classical and Near Eastern Studies and Prof. Dingie Janse van Rensburg, Professor Extraordinary at the Centre for Health Systems Research and Development, also obtained B3-ratings. Prof. Naudé is the first B-rated researcher in the Faculty of Humanities.
Prof. Helene Strauss obtained the highest rating (Y1) for a UFS young scholar in the Humanities.
In total, the NRF rated researchers at the UFS grew from 95 in 2011 to 109 in 2012, a growth of almost 15 percent.
The NRF ratings committee consist of three reviewers from South Africa and three from abroad. A rating is valid for six years and researchers must reapply for rating before the end of that period.
For a B1-rating all reviewers must be firmly convinced that the applicant enjoys considerable international recognition for the high quality of the researcher’s recent output, with some indicating that the researcher is a leading international scholar in a field. For a B3-rating most of the reviewers must be convinced that the researcher enjoys international recognition for the high quality and impact of the research.
Prof. Jonathan Jansen, Vice-Chancellor and Rector, said in the UFS Research Report “The UFS now has among the highest number of NRF-rated scientists per size of the academic faculty and we have seen the productivity graph bear witness to a record growth in our funded research outputs; we have won our first-ever NRF/DST Research Chairs. In each of these achievements, the excellence we seek comes with and through the diversity we celebrate.”
More ratings and renewals were expected by the time of Bult went to print.. More than 35 researchers applied for ratings or renewal of ratings.
  • Colleagues who were admitted to the prestigious Academy of Science of South Africa (ASSAf) are Profs. Pumla Gobodo-Madikizela, Driekie Hay, Heidi Hudson, Lodewyk Kock, Odireleng Ntwaeaborwa, Hugh Patterton, Ian Phimister and Melanie Walker. ASSAf was established in 1996 with the mission of using science for the benefit of society. New members are elected after nomination by four existing members (at least two of whom do so from personal knowledge of the candidate). ASSAf has some 350 members and represents South Africa in the international community of science academies.
  • Dr Marieka Gryzenhout of Plant Sciences became a member of South African Young Academy of Science (SAYAS). SAYAS celebrated its first year in 2012. It was launched as a means to enable South Africa’s young scientists to fully participate in locally and internationally relevant research and development agendas. Prof. Aldo Stroebel, Director: Internationalisation, is also a member of SAYAS.

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept